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Can microbes compete with cows 
for sustainable protein production -  
A feasibility study on high quality 
protein
Mike Vestergaard, Siu Hung Joshua Chan & Peter Ruhdal Jensen
An increasing population and their increased demand for high-protein diets will require dramatic 
changes in the food industry, as limited resources and environmental issues will make animal derived 
foods and proteins, gradually more unsustainable to produce. To explore alternatives to animal derived 
proteins, an economic model was built around the genome-scale metabolic network of E. coli to study 
the feasibility of recombinant protein production as a food source. Using a novel model, we predicted 
which microbial production strategies are optimal for economic return, by capturing the tradeoff 
between the market prices of substrates, product output and the efficiency of microbial production. 
A case study with the food protein, Bovine Alpha Lactalbumin was made to evaluate the upstream 
economic feasibilities. Simulations with different substrate profiles at maximum productivity were used 
to explore the feasibility of recombinant Bovine Alpha Lactalbumin production coupled with market 
prices of utilized materials. We found that recombinant protein production could be a feasible food 
source and an alternative to traditional sources.
The global population is estimated to reach 9.1–9.7 billion by 2050, with approximately an 1.8-fold increase in 
income per capita1,2. Food consumption is predicted to become increasingly based on animal derived products 
– mainly due to increased wealth in developing countries2. The production of valued protein rich foods, such as 
milk is estimated to increase by 62% (from production levels of 2005–2007 to 2050, i.e. from 664 to 1 077 million 
tons)2. Animal derived products are less sustainable to produce compared to their vegetable counterparts. This is 
why it is important to either produce products that can be used as an alternative or develop better ways of produc-
ing animal derived products. Certain subcomponents derived from milk, especially proteins, are important due 
to their functionality and nutritional value, which are why technologies that can produce these more sustainably 
would be beneficial. Recombinant protein production could provide an alternative source of milk proteins, as 
engineered microorganisms have the advantage of producing specific compounds in elevated amounts3. This 
approach has revolutionized the biotechnology and pharma industry4,5 though proteins for human consumption 
have not yet been subject to such trends, as competition from traditional industries and GMO controversies 
have been of concern. Proteins used as ingredients in the food industry have traditionally been based on isolates 
from natural sources – with milk proteins as a major driver6. The nutritional and functional capacities of certain 
milk proteins make them an obvious choice when fortifying or formulating products and the production of milk 
proteins by recombinant means could offer a sustainable additional source in the future. It is however nontrivial 
to evaluate the economic feasibility of such an endeavor, as cost of substrate, price of milk proteins and technical 
performance becomes decisive.
The Genome-Scale Metabolic Network (GSMN) is the collective knowledge of metabolic routes within a given 
organism, while Flux Balance Analysis (FBA) is the simulation within these networks that allows metabolites to 
change accordingly7. The sandbox like nature of the GSMN makes it possible to use it as a tool for simulating met-
abolic conversions and growth. Here we made a model where the upstream feasibility of recombinant protein pro-
duction was explored within the GSMN of the E. coli (iAF1260)8 for the milk protein, Bovine Alpha Lactalbumin 
(α -La) (Uniprot: P00711). Briefly, this was achieved by associating the required metabolites for α -La production 
with costs and dynamically simulating the optimal production with respect to different objective functions, i.e. 
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maximizing productivity using sugar and soybean meal as substrates. Simulations within the model were assessed 
and evaluated in terms of economic potential. The results indicated a potential for recombinant food protein 
production in the future.
The dairy industry has within the last decades been revolutionized with respect to processing and purifying 
proteins from milk and whey. Proteins can be isolated from whey, a side product generated during cheese man-
ufacturing, which historically has been a waste product. Revenue generated from protein extraction has been 
increasing in recent decades and has comprised a growing part of the total revenue of the dairy industry. The 
market for whey proteins has seen a predominant growth within whey protein isolates (WPI – above 90% pro-
tein purity) compared to lesser whey protein concentrates (WPC34–34% protein purity) within the last decade, 
implying that pure proteins with functional properties are in high demand. The total production of WPI was 
36.800 mt in 2014 for the US, which is an increase of 2.5 fold compared to the total production in 2006–14.400 mt 
(http://usda.mannlib.cornell.edu/MannUsda/viewDocumentInfo.do?documentID= 1052). WPI’s or fractions 
of these are produced by a variety of filtration systems and chromatographies6. Among the products formu-
lated with whey proteins are infant formulas, where especially the Bovine α -La is used to mimic the content of 
Humane α -La found in human milk due to its beneficial properties6,9. α -La is sold at different purities in powder 
form - ranging from 35% to 65% α -La purity in 80–90% total protein content. The price range lies approximately 
between 15 €/kg to 25 €/kg according to purity as of 2014 (Inquiry at international α -La vendor).
Results
The conversion of lower valued carbon sources into higher valued food proteins by microbial means could 
become a sustainable contribution in the future and it is therefore relevant to explore its economic feasibility. 
The created model utilizes the E. coli (iAF1260) base model and adds the option to shift a part of the metabolites 
designated for growth into recombinant protein production. This is achieved by adding, uptake rates of relevant 
metabolites, metabolic cost of protein production and ribosomal elongation rates, while the feasibility is evalu-
ated by assigning cost to substrate materials and gain from produced α -La - as described in the method section. 
Process simulations were obtained by exhaustively maximizing productivity within the hypothetical outcome 
of cell growth and recombinant protein production at different substrate compositions. The results from the 
simulations are depictured as 3 dimensional surface planes where the individual coordinates represent different 
simulated processes with the global maximum being the best process. The model does not impose any time 
requirements and the different processes vary in time – as described in the method section.
Productivity of α-La. Results from the simulations where productivity were optimized are presented in 
Fig. 1 as a plot with yield per substrate, substrate compositions and productivity on the X, Y and Z axis respec-
tively. A color layer representing the economic return based on the substrate price is furthermore applied and 
utilizes a per hour unit in order to compare simulations with different process times. The plot shows that the 
highest productivity occurs at a process with an average of 0.2 g produced protein per gram substrate (20%) with 
a substrate composition of 95% sugar and 5% soybean – indicating that some amino acid supplements in the 
form of soybean meal are favorable compared to media based on sugar exclusively. This demonstrates that a more 
expensive and less energy dense substrate like soybean meal can be applicable, as a greater flux of metabolites 
matters when maximizing productivity. The upstream process takes 11 hours and converts the initial substrate 
into α -La worth 21.8 times the value of the starting material. The underlying growth profile for the process is 
exponential with a specific growth rate that starts of as a plateau at a high rate, then declines over the course of the 
process and ends at a plateau of lower specific growth rate towards the end. The substrates are fully utilized during 
the process (which is not the case for all the simulations) and the ribosomes are at maximum capacity throughout 
the simulations. See Supporting Data - 5 for supporting figures. The economic return in the model is derived 
from the market price of 60% pure α -La, which includes all related costs e.g. expenditures for purification and 
distribution. The simulations potential economic return is thereby lower as additional cost needs to be applied to 
account for the further processing.
Figure 1. Simulation of economic productivity. The plot depictures α -La fermentations at maximized 
productivity with yield per substrate, substrate compositions and economic return based on the substrate price 
per hour on the X, Y and Z axis respectively. The global maximum represents a fermentation, which converts 
the initial substrate into α -La worth 21.8 times the value of the starting material. The fermentation is simulated 
to take 11 hours and require the substrate to compose of 5% soybean and 95% sugar.
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Maximizing productivity provides simulated processes where the balance between biomass and protein pro-
duction are shifted towards biomass, as increased biomass facilitates larger fluxes of protein over time compared 
to yield maximized processes. For situations where time is less of a concern and process yield is more important, 
the shift towards protein production can be utilized to increase the feasibility per cost of substrate. By recogniz-
ing that productivity always will be a desirable process parameter, the surface plane of the productivity plot was 
analyzed and a plot with the final process yield was created based on the productivity simulations. The plot is pre-
sented in Fig. 2 with yield per substrate, substrate compositions and process yield on the X, Y and Z axis respec-
tively. The color over layer represents the economic return based on the substrate price. The plot demonstrates 
that higher process yields can be obtained at simulations with higher average produced α -La per gram substrate. 
The maximum process yield is present in a process with a 52 fold economic return per substrate at 0.5 gram pro-
duced protein per gram substrate at 100% sugar media composition. The process takes approximately 300 hours 
and is therefore likely to be associated with costs that would decrease the actual gain of running the process (labor 
and overhead) and technical issues (protein stability and cell death). Figure 3 presents the total fermentation time 
utilized in the simulation of economic productivity (Fig. 1) and simulation of economic yield (Fig. 2).
The process yield and the productivity represent two bases of the production strategy, namely cost-efficiency 
and time-efficiency. The solutions existing in between are compromises and can be applied for complex processes 
where neither of the two parameters is completely dominating the economic feasibility. A combination of the 
two objectives can be maximized with the parameter α depending on the demand or growth of the market, see 
equation 1.
α α


 + −



Process yield
Max process yield
Productivity
Max productivity( )
(1 )
( ) (1)
where 0 < α < 1.
The simulated upstream production of α -La demonstrates the potential of recombinant protein production in 
microorganisms and the cellular machinery that supports it. Processes based on microorganisms could become 
an additional food source and is worth considering when discussing the possible solutions for future supply of 
high quality proteins for human consumption10. The further downstream process of a theoretical α -La produc-
tion would determine the overall feasibility, as purification costs can be significant in biotech processes.
Figure 2. Simulation of economic yield. The plot depictures α -La fermentations at maximized productivity 
with yield per substrate, substrate compositions and economic return based on the substrate price on the X, Y 
and Z axis respectively. The global maximum represents a fermentation, which converts the initial substrate 
into α -La worth 52 times the value of the starting material. The fermentation is simulated to take 300 hours and 
require the substrate to compose of 100% sugar.
Figure 3. Total fermentation time. The plot depictures α -La fermentations at maximized productivity with 
yield per substrate, substrate compositions and time on the X, Y and Z axis respectively. The simulations vary 
greatly in total time, from a few hours to almost two weeks. Simulations with high yield per substrate do in 
general take longer. The rapid decline along the 60% yield (g/g) simulations seen in Figs 2 and 3 is a result of the 
cell growth and recombinant protein production being unable to maintain suitable productivity for prolonged 
fermentations.
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Processing. E. coli is a prokaryote industrial platform which has been widely used for recombinant pro-
tein production in biotech and pharmaceutical applications and could be a candidate for recombinant food 
protein production. While there are a variety of different technical obstacles that makes recombinant pro-
tein production challenging, it is important to recognize that the underlying biological system is capable 
of converting biomass into specific products at a rapid pace, which could be utilized to secure adequate 
amounts of quality food proteins. Different strategies employed in recombinant protein production enable 
streamlined downstream processes and recombinant products can in general be rendered available for pro-
cessing by multiple initial strategies, including intracellular recovery, extracellular secretion or intracellular 
recovery from inclusion bodies11. The cost of purification is a significant factor that affects the overall fea-
sibility, though the current market of GMO food graded vitamins, preservatives and enzymes suggests that 
cost effective processes are available.
The cost of handling and terminating GMO material is an additional expenditure for any recombinant pro-
cess, though the cost can be mitigated by recycling the microbial biomass produced. One approach is to seek 
authorization to use specific terminated GMO as feed products. Terminated GMOs used as feed material for 
animals can create value associated with sales and reduced cost in waste management, providing a sustainable 
alternative. Insulin producer Novo Nordisk and amino acid producer Ajinomoto Eurolysine SAS are examples 
of companies with different types of end-products which have sought such an authorization for some of their 
terminated GMO by-products (http://ec.europa.eu/food/dyna/gm_register/index_en.cfm).
Legislative concerns. The use of GMO derived ingredients intended for human consumption is under leg-
islative control. Approval from governmental authorities is granted if sufficient documentation is presented in 
regards to production methodology and consumer safety. The probability of achieving usage authorization for 
α -La isolates from E. coli can be evaluated based on prior cases. The US FDA GRAS Notice Inventory, lists food 
ingredients that are regarded as safe to use and includes protein isolates from milk and whey (See GRN No. 37 
and GRN No. 444 (http://www.accessdata.fda.gov/scripts/fdcc/). E. coli strain K-12 is among other used in the 
production of the recombinant enzyme, Chymosin, applied in cheese manufacturing. Chymosin is regarded as 
safe to use, when produced in certain non-pathogen microorganisms, including E. coli strain K-12 - according to 
§ 184.1685 (http://www.gpo.gov/fdsys/pkg/CFR-2012-title21-vol3/pdf/CFR-2012-title21-vol3-sec184-1685.pdf). 
Chymosin is an example of a food ingredient that is dominating the market, as the natural source is not avail-
able in sufficient amounts nor at attractive prices. For theoretical α -La protein isolates from E. coli K-12, both 
compound and organism have been approved separately in prior cases for food formulation, which indicate that 
authorization could be obtained.
Production. The formation of amino acids followed by their subsequent polymerization into proteins is 
a notable expenditure in metabolites, as it requires both substrate derived building blocks and energy in the 
form of ATP12,13. The increased cost of amino acid compared to sugar does not decrease the feasibility of using 
amino acids in the model, as higher amino acid fluxes results in higher productivity of the recombinant protein. 
The capacity of the TCA cycle has been reported as a limiting factor during recombinant protein production in 
E. coli on minimal medium as the formation of intermediates for amino acids and intermediates designated for 
oxidative phosphorylation competes for substrates14. Media composition is an important parameter for indus-
trial processes. The shift between protein production and growth is only limited in the model by the metabolites 
required for mRNA and subsequently protein synthesis, which implies two things: (1) the translation initiation of 
recombinant protein is not limited by physical constraints and (2) the utilized strain is capable of mimicking the 
required production profile through a controllable system. Elaborate algorithms and models exist that can over-
come limitation at translation initiation by rational design15,16, while several controllable systems for protein pro-
duction are available in bacteria at industrial scale17. Protein translation involves four phases: initiation, elongation, 
termination and ribosome turnover, where initiation usually is the limiting factor in recombinant production11,16 
implying that the applied genetic material is limiting its own protein synthesis (inadequate transcription levels, 
mRNA instability, unfavorable ribosomal-binding-site complex). In the case where initiation limitations are over-
come, the native genetic blueprint of the organism becomes the limiting factor for recombinant protein synthesis. 
In such cases the protein elongation rate in conjunction with the amount of ribosomes becomes the limiting rate 
- as detailed in the model. In vivo studies additionally suggest that the maximum elongation rate per ribosome is 
higher than the experimental observed18.
Perspective. The data used in the simulations are sensitive to fluctuations in cost of substrates and protein 
prices. A sensitivity analysis could be incorporated to predict feasibility based on projected trends in the market. 
To compete with traditional production the conversion of input material into α -La needs to be economically 
feasible, though the initial cost associated with acquiring production capacities at large scale, developing strain(s) 
and acquiring legislative approval, determines if it is an attractive investment. Alternative production methods 
utilizing recombinant protein production could become an important source for ingredients that would other-
wise become scarce in the future or unsustainable to produce. A food industry integrated with recombinant pro-
duction capabilities would be less susceptible to traditional negative events and could create novel products not 
currently available. Recombinant α -La production and other milk proteins could be incorporated into the dairy 
industry by utilizing their existing pipeline and infrastructure, while strains able to utilize the available material 
in the dairy industry could be further integrated into the process.
Bovine α -La is used as a substitution to Human α -La in infant formulas, as there are no feasible sources of 
Human α -La. Recombinant human α -La production could be envisioned, though controversies could arise due to 
the human origin. The controversy surrounding the use of GMOs for food production needs to be addressed and 
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superior products, both in terms of quality and cost could help alleviate the negative image surrounding recom-
binant proteins for food. This in addition to rigorous safety tests would be needed to make recombinant products 
become marketable.
Assumptions and limitations. The data used for substrate uptake and protein chain elongation rate are 
from different E. coli strains obtained at slightly different experimental setups than that of the base model. We esti-
mated the data to be sufficiently accurate to describe and limit protein production in conjunction with the GSMN, 
and to evaluate the initial feasibility of recombinant α -La production. The model does furthermore assume that 
the only burden imposed on the cells is the metabolic cost derived from the recombinant production, which is a 
simplification. Effects such as, ATP-dependent proteolytic degradation by the proteasome, increased chaperone 
requirements or protein instability are therefore neglected19. The biomass accumulation and the derived volume 
for optimal growth have not been taken into consideration and different fermentation modes have not been 
explored. The price of α -La is derived from its purity and functional properties and the model assumes that these 
properties are kept.
Discussion
The production of food proteins by GMO organisms could be one solution to an increasing population with a 
demand for quality proteins and sustainable production methods, though such solutions are challenging to eval-
uate economically. It is therefore important in an industrial context to have models that can translate biological 
data and processes into economic values and thereby evaluate different innovative ideas. The GSMN system 
allows simulations of growth and product production, which with an emphasis on economic feasibility and pro-
cess parameters can be used as an evaluation tool for industrial processes. Some works exist that cover certain 
requirements for the industry20–22 though little has been done to bridge the economic and metabolic processes rel-
evant for recombinant production. In this study, we created a novel model, to evaluate the production of recom-
binant α -La in E. coli by utilizing ribosomal data in conjunction with the base model iAF1260. We found the 
conversion of substrate into product could result in approximately 22 fold economic return in a rapid upstream 
process at maximized productivity, which potentially could provide a sufficient income for the feasibility of an 
overall process. It is further possible to increase the cost efficiency by prolonging the process and obtaining more 
α -La by utilizing more time. With the model as the metabolic basis it is possible to build integrated economic 
models based on markets and processing inputs and study their performance. We hope that this kind of interdis-
ciplinary approach can evaluate recombinant ways of producing products and support a sustainable translation 
into a bio based economy.
Methods
Protein synthesis general. The potential feasibility of recombinant α -La production was assessed in 
the framework of GSMNs by assigning economic values to input materials and output α -La. Commercial 
available sugar and soybean meal, reported by the World Bank, at prices of 0.41 €/kg and 0.50 €/kg respec-
tively for Europe in 2014 (Dollar to euro = 0.95)23 were used as input material. For simplicity, the sugar and 
soybean meal were assumed to be in their monomeric forms: glucose, fructose and amino acids, while no 
other compounds were accounted for in the simulations. The respective product specifications can be seen in 
Supporting Data 1. The maximum uptake rates for amino acids were set according to the exponential growth 
data presented24 for E. coli and the glucose and oxygen maximum uptake rates were set accordingly8. The max-
imum uptake rate of fructose was arbitrarily set to that of glucose and defined, as an uptake that only occurs 
after glucose depletion. See Supporting Data 2 for a complete list of uptake rates. The biochemical reaction of 
protein production was written in terms of the metabolites in the GSMN with the stoichiometry for amino 
acids calculated from the coding sequence of α -La and the ATP cost estimated from protein synthesis and 
RNA transcription. Polymerization of amino acids into protein was set to a metabolic cost of 4.5 ATP per 
amino acid, reflecting aminoacyl-tRNA synthesis (ATP to AMP) and peptide bond formation at ribosomal 
level (2GTP to 2GDP) and an additional 0.5 ATP for miscellaneous quality processes12,25. mRNA synthesis 
was set to the metabolic cost of mRNA elongation (2.0 ATP)12, with 20 translations per mRNA molecule26 
The synthesis of mRNA building blocks was neglected, as reuse occurs. A total of 41.6 mmol ATP per g α -La 
were used in the simulations. See Supporting Data 3 for further information. The synthesis rate of protein was 
coupled to the specific protein elongation rate at different cellular growth rates for E. coli per cell mass and 
ribosome content as reviewed in ref. 26. See Supporting Data 4 for further explanation and information on 
precise implementation. The market price of 25 €/kg for α -La extracts purified to the extent of 60% purity was 
used to generate a corrected theoretical price of 41,7 €/kg α -La. The database BioNumbers was used to find 
valuable information27.
Optimization model for predicting optimal medium composition and protein yield -Bilevel 
dynamic optimization model. The reaction was added to network by inserting the column vector of sto-
ichiometry into the stoichiometric matrix N. The capability of the production strain to utilize different sub-
strates is encoded in N and constrained by the maximum substrate uptake rates. Given this capability, a bilevel 
dynamic optimization model was developed to predict the optimal medium composition and the protein yield to 
be achieved such that the economic return and the rate of return would be maximized:
www.nature.com/scientificreports/
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In the above model, the initial amounts of the Nex extracellular substrates Sk(0) for k = 1, 2, … , Nex (7) and the 
protein yield on carbon source YP/carbon (8) are the constant control variables of the outer-level decision. The ter-
minal time T is not fixed (9) so that the optimal time for stopping a batch would also be determined. The 
inner-level variable is the flux distribution µ=  v v v v vv [ ]P N
ex
N
in T
1
ex
1
in
ex in
 where μ is the specific 
growth rate (h−1), approximated by the biomass production flux in the GSMN, vP the specific production rate of 
protein(g gdw−1 h−1), vk
ex the exchange flux of the k-th extracellular metabolite (mmol gdw−1 h−1) and vk
in the flux 
of the k-th intracellular reaction (mmol gdw−1 h−1) assuming there are Nin intracellular reactions. The convention 
of uptake flux being negative and secretion flux being positive for vk
ex was adopted.
Flux Balance Analysis (FBA) with protein yield constraint as the Inner-level problem. The flux 
distribution v is subject to the optimality criterion of maximum growth rate (10), the constraint of mass balance 
(11), upper bounds (ubk) and lower bounds (lbk) for intracellular fluxes (12) and exchange fluxes (13) respectively. 
sgn(Sk) is the sign function for Sk so that when substrate k is used up, i.e. Sk = 0 then vk
ex ≥ 0 and substrate k cannot 
be consumed anymore in the GSMN. Constraints (10–13) are the standard flux balance analysis FBA. An addi-
tional protein yield constraint (14), where δk
carbon = 1 if substrate k is a carbon source or δk
carbon = 0 otherwise; 
MWk is the molecular weight (g mmol−1) of substrate k; and −vk
ex ,  is the negative part of the flux, i.e. 
=−v min v{ , 0}k
ex
k
ex, . This constraint ensures that a fraction of the carbon source taken up (in gram) is converted 
into the target protein. Constraints (10–14) collectively form the inner-level problem. Given the substrate availa-
bility Sk and the required protein yield YP/carbon, a steady-state flux distribution maximizing growth rate could be 
determined.
Dynamic Flux Balance Analysis (dFBA) and cost constraint as the outer-level problem. 
Constraints (3–5) are the state equations that describe the rate of change of biomass X (in gdw), protein amount 
P (in gram) and extracellular metabolite Sk (in mmol) respectively. These constraints combined with the 
inner-level problem (10, 11–14) is equivalent to dynamic flux balance analysis (dFBA)28,29. To optimize the eco-
nomic return of the fermentation process described by dFBA, the total cost of the initial substrate amounts Sk(0) 
is fixed to be m (in any currency) in constraint (6) where ck is the cost of one gram of substrate k. With the cost 
fixed, the outer-level objective function (2) maximizes a convex combination of the protein produced P(T) and 
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the production rate P(T)/T. This equivalently maximizes the economic return (price/gram)x P(T)/m and the rate 
of return (price/gram)x P(T)/T/m.
Solution technique. The presented optimization model is dynamic, non-linear and bilevel and thus very dif-
ficult to solve in general. In the particular case of two available substrates, however, there are only two outer-level 
decision variables, namely the yield and the amount of substrate 1, because the amount of substrate 2 would be 
fixed by constraint (6). Note that both the yield and substrate amount are bounded below and above respectively. 
In this case, the problem can be solved by exhaustive search through the whole 2-dimensional solution space. 
Given the substrate amount and the yield, dFBA is performed and the optimal time allowing the maximum objec-
tive function value and the corresponding state variables are taken as a solution.
The model is concentration free and operates with grams and moles. The simulations have been done with 
input material equal to 0.004 € which is approximately 10 grams of substrate - depending on the substrate compo-
sition. The initial biomass is 0.01 g for the simulations and gas and adequate stirring is presumed.
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